Pacira BioSciencesPCRX
PCRX
0
Funds holding %
of 7,398 funds
0
Analysts bullish %
of 5 analysts
Fund manager confidence
Based on 2024 Q4 regulatory filings by fund managers ($100M+ AUM)
696% more call options, than puts
Call options by funds: $19.8M | Put options by funds: $2.49M
21% more capital invested
Capital invested by funds: $779M [Q3] → $942M (+$162M) [Q4]
0% more funds holding in top 10
Funds holding in top 10: 1 [Q3] → 1 (+0) [Q4]
4% less repeat investments, than reductions
Existing positions increased: 76 | Existing positions reduced: 79
8% less first-time investments, than exits
New positions opened: 37 | Existing positions closed: 40
3% less funds holding
Funds holding: 237 [Q3] → 231 (-6) [Q4]
3.95% less ownership
Funds ownership: 112.17% [Q3] → 108.22% (-3.95%) [Q4]
Research analyst outlook
5 Wall Street Analysts provided 1 year price targets over the past 3 months
Low target
$18
25%
downside
Avg. target
$34
40%
upside
High target
$70
191%
upside
5 analyst ratings
3 positive
60%
2 neutral
40%
0 negative
0%
Barclays Balaji Prasad 30% 1-year accuracy 13 / 44 met price target | 0%downside $24 | Overweight Maintained | 28 Feb 2025 |
Needham Serge Belanger 48% 1-year accuracy 58 / 121 met price target | 33%upside $32 | Buy Maintained | 28 Feb 2025 |
HC Wainwright & Co. Oren Livnat 62% 1-year accuracy 31 / 50 met price target | 191%upside $70 | Buy Maintained | 28 Feb 2025 |
Truist Securities Les Sulewski 29% 1-year accuracy 2 / 7 met price target | 4%upside $25 | Hold Upgraded | 30 Jan 2025 |
RBC Capital Gregory Renza 28% 1-year accuracy 21 / 75 met price target | 25%downside $18 | Sector Perform Reiterated | 14 Jan 2025 |
Financial journalist opinion
Based on 98 articles about PCRX published over the past 30 days
Neutral
GlobeNewsWire
15 hours ago
Pacira BioSciences to Participate in Fireside Chat at the 24th Annual Needham Virtual Healthcare Conference
BRISBANE, Calif., April 01, 2025 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (Nasdaq: PCRX), the industry leader in its commitment to deliver innovative, non-opioid pain therapies to transform the lives of patients, today announced that it will participate in an analyst-led fireside chat at the 24th Annual Needham Virtual Healthcare Conference at 11:45 AM ET on Monday, April 7, 2025.
Positive
Zacks Investment Research
1 week ago
Pacira Surges 66.8% in Six Months: How Should You Play the Stock?
PCRX has put up a strong performance in six months with shares rallying 66.8%. However, its sole dependence on Exparel for growth is a concern.
Neutral
Accesswire
1 week ago
Pacira BioSciences, Inc. (PCRA) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Stockholders to Contact the Firm to Learn More About the Investigation
NEW YORK CITY, NY / ACCESS Newswire / March 20, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Pacira BioSciences, Inc. ("Pacira" or "the Company") (NASDAQ:PCRA). Investors who purchased Pacira securities prior to August 2, 2023, and continue to hold to the present, are encouraged to obtain additional information and assist the investigation by visiting the firm's site: bgandg.com/PCRA.
Positive
Seeking Alpha
2 weeks ago
Pacira BioSciences: Back On An Uptrend After Positive Developments
Pacira BioSciences, Inc.'s stock is up 33% since my last “Buy” rating, driven by strategic moves and market overreaction correction. The company has secured a new patent for its lead pain therapeutic, Exparel, delaying generic market entrants, and potentially protecting its market share until mid-next decade. Vertex's Journavx launch may boost awareness for non-opioid pain relief, benefiting Pacira's Exparel under the NOPAIN Act.
Neutral
Accesswire
2 weeks ago
Levi & Korsinsky Notifies Shareholders of Pacira BioSciences, Inc. (PCRX) of a Class Action Lawsuit and an Upcoming Deadline
NEW YORK, NY / ACCESS Newswire / March 14, 2025 / If you suffered a loss on your Pacira BioSciences, Inc. (NASDAQ:PCRX) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/pacira-biosciences-inc-lawsuit-submission-form?prid=136169&wire=1 or contact Joseph E. Levi, Esq.
Neutral
GlobeNewsWire
2 weeks ago
Pacira BioSciences Confirms Receipt of Director Nominations from DOMA Perpetual
-- No Shareholder Action Required at This Time -- PARSIPPANY, N.J., March 14, 2025 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (Nasdaq: PCRX), the industry leader in its commitment to deliver innovative, non-opioid pain therapies to transform the lives of patients, today confirmed that DOMA Perpetual Capital Management LLC (“DOMA”) has nominated three candidates to stand for election to the Pacira Board of Directors (the “Board”) at the Company's 2025 Annual Meeting of Stockholders.
Neutral
Accesswire
2 weeks ago
Levi & Korsinsky Announces the Filing of a Securities Class Action on Behalf of Pacira BioSciences, Inc.(PCRX) Shareholders
NEW YORK, NY / ACCESS Newswire / March 14, 2025 / If you suffered a loss on your Pacira BioSciences, Inc. (NASDAQ:PCRX) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/pacira-biosciences-inc-lawsuit-submission-form?prid=136135&wire=1 or contact Joseph E. Levi, Esq.
Neutral
Accesswire
2 weeks ago
Shareholders That Lost Money on Pacira BioSciences, Inc. (PCRX) Urged to Join Class Action - Contact Levi & Korsinsky to Learn More
NEW YORK, NY / ACCESS Newswire / March 14, 2025 / If you suffered a loss on your Pacira BioSciences, Inc. (NASDAQ:PCRX) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/pacira-biosciences-inc-lawsuit-submission-form?prid=136106&wire=1 or contact Joseph E. Levi, Esq.
Neutral
PRNewsWire
2 weeks ago
DOMA Perpetual Nominates Three Highly Qualified Candidates for the Board of Pacira BioSciences
Pacira's Stock is Down 76% Over the Last Decade, While the Board and Management Have Enriched Themselves at a Cost of Half a Billion Dollars, Roughly 50% of the Current Market Cap Under CEO and Board Member Frank Lee, the Stock Price Has Declined 33%; He is Pushing for Higher Compensation Packages for Management While Burdening Shareholders with New Risks; DOMA Believes His Views on Capital Allocation Are Misaligned With Shareholder Interest and He Has No Track Record of Creating Shareholder Value Change to the Board's Composition is Critical to Accelerate Shareholder Return and to Correct a Decade of Corporate Abuse and Lack of Stock Price Returns DOMA's Three Highly Qualified Nominees Possess Vast Experience in Strategic Capital Allocation, Risk Management, Healthcare Banking and Intellectual Property Law and Litigation MIAMI , March 14, 2025 /PRNewswire/ -- DOMA Perpetual Capital Management LLC ("DOMA Perpetual") is a fundamentals-based, value-oriented investor that, together with the other participants in its solicitation (collectively "DOMA" or "we"), beneficially owns approximately 4.2% of the outstanding shares of common stock of Pacira BioSciences (NASDAQ: PCRX) ("Pacira" or the "Company").i DOMA today announced its nomination of three highly skilled director candidates to Pacira BioSciences Board of Directors (the "Board"): Joseph Kromholz, Philip Pucciarelli and Eric de Armas. DOMA believes electing these nominees is critical to address the Board's lack of financial sophistication and legal expertise and to correct its value-destroying capital allocation strategy.
Neutral
Accesswire
2 weeks ago
Levi & Korsinsky Notifies Shareholders of Pacira BioSciences, Inc. (PCRX) of a Class Action Lawsuit and an Upcoming Deadline
NEW YORK, NY / ACCESS Newswire / March 14, 2025 / If you suffered a loss on your Pacira BioSciences, Inc. (NASDAQ:PCRX) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/pacira-biosciences-inc-lawsuit-submission-form?prid=135985&wire=1 or contact Joseph E. Levi, Esq.
Charts implemented using Lightweight Charts™